Zimbabwe has rejected a major US health deal valued at $367m (272 million pounds) over five years because of Washington's insistence on sensitive data.
This rejection was revealed following a official document dated December was disclosed, revealing that President Emmerson Mnangagwa believed the arrangement was "skewed".
An official spokesperson later explained that the United States was seeking biological samples for research and commercial gain while refused to guarantee the resulting advantages from any future medical innovations.
"We will now turn to the difficult and regrettable process of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the US had donated over $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has appealed for more negotiations to find a deal agreeable to both sides so the country's vital HIV treatment initiative can proceed.
Wider Implications
This development comes after a comparable case in Kenya, where a court suspended a similar health funding agreement after concerns were raised about the security of citizens' medical information.
Since resuming office last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump stated its spending was "inefficient" and his government was seeking government-to-government agreements to enhance transparency and responsibility.
As per reports, 16 nations in Africa have to date agreed to similar health pacts, constituting over $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this collaboration could have provided extraordinary advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently on antiretroviral therapy through US-supported programmes," Tremont said.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any equivalent guarantee of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that provided information," he stated.
"Effectively, our country would supply the basic resources for scientific discovery without any certainty that the final treatments would be available to our citizens if a new pandemic emerge."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of one-on-one deals were disrupting frameworks already set up through the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to manage future global health emergencies.
"This mechanism is designed to guarantee that when a country provides its information, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the capability to create them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage continued dialogue with our American counterparts on how subsequent collaboration might be structured in a manner that honours the independence and dignity of both nations."
Medical Community Reaction
Medical experts stated it recognised the official position, but recommended that talks should continue since a large portion of the country's Aids initiatives relied on foreign aid.
"In cases where specific concerns exist, including those involving data governance or implementation frameworks, these can often be resolved through technical clarification and mutually agreed protections," it commented.
This impasse highlights the ongoing debate between receiving crucial foreign assistance and protecting a country's data in an ever more data-driven world.